Ten-year follow-up of pediatric patients with non-hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation

Giulino‐Roth, Lisa; Ricafort, Rosanna; Kernan, Nancy A.; Small, Trudy N.; Trippett, Tanya M.; Steinherz, Peter G.; Prockop, Susan E.; Scaradavou, Andromachi; Chiu, Michelle; O’Reilly, Richard J.; Boulad, Farid

doi:10.1002/pbc.24722

Cited by 41 publications

(37 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The graft versus ALCL effect is also supported by the observation that disease control was obtained in the present series in a girl who had relapsed after a transplant with donor lymphocyte injections, a procedure previously reported to have been efficient for the treatment of post transplant relapses in a few cases of adult aggressive T-cell lymphoma. 15,16 Although the efficacy of this procedure in relapsed/refractory ALCL has been clearly shown in our series as in most series in the literature, the benefit associated with the reduction in treatment failure has to be weighed against the increased risk of mortality and long-term morbidity due to allo-SCT. In our series, as in most series in the literature, toxicity was the main cause of death with a 5-year TRM rate estimated at 24% in the whole series.…”

Section: Discussionmentioning

confidence: 93%

“…However, our results are consistent with those of other studies, based on smaller series of patients with refractory or relapsed ALCL ( Table 4) that reported EFS rates between 46 and 75%. [4][5][6][7][8][9]15 In the three largest series, relapse rates were relatively low ranging from 10 to 28%, whereas toxicity-related mortality accounted for a large proportion of the events. Owing to the small numbers of patients included in each of these reports, no prognostic factor was identified but the authors pointed out the efficiency of this treatment in heavily pre-treated patients and in patients who had previously experienced disease progression under first-line chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC

Strullu

Thomas

Deley

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a treatment option for relapsed anaplastic large cell lymphoma (ALCL) in children, but reports on its efficacy in this disease are still limited. We analyzed data concerning 34 patients under 18 years of age prospectively registered in the French SFGM-TC database, who had undergone an allo-SCT for the treatment of ALK+ ALCL between 1993 and 2011. At transplant, 28 patients (82.4%) were in CR, whereas 6 exhibited detectable disease. Conditioning regimens were mostly myelo-ablative (n = 31). With a median follow-up of 6 years, 5-year overall and event-free survival rates were 70% (SE = 8%) and 58% (SE = 9%), respectively. The 5-year cumulative incidence of relapse and treatment-related mortality was 18% (SE = 7%) and 24% (SE = 8%), respectively. Six patients had relapsed (median time, 141 days (35-235)). A durable CR had been obtained in 4/6 patients after injection of donor lymphocytes (n = 1) or vinblastine-corticosteroid therapy (n = 3). Ten patients had died, eight due to transplant toxicity and two due to progressive disease. Allo-SCT is an efficient treatment for pediatric patients with high-risk relapsed ALK+ ALCL. However, the overall morbidity of allo-SCT raises questions about its place, given the efficacy of targeted agents currently under development in this disease. 1 Treatments based on multiagent chemotherapy over a short period (o 6 months) are successful in most patients. Bone Marrow Transplantation2 However, relapses occur in 25-30% of cases, mostly within 6 months after treatment.3 CR can once again be achieved at relapse in most patients with a wide variety of chemotherapy regimens. Thus, the 2-year overall survival rate in children treated for an ALCL exceeds 85% in the most recent reports and has attained 94% in the ALCL99 international trial.2 In most patients, the treatment strategy for relapse comprises autologous or allogeneic hematopoietic stem cell transplantation (allo-SCT) after a CR. The feasibility and efficacy of allo-SCT with good engraftment, acceptable toxicity and event-free survival rate ranging from 45 to 75% has been demonstrated in small series and case reports published so far.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC

Strullu

Thomas

Deley

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…В ра-боте L. Giulino-Roth и соавт. 10-летняя ОВ больных с рецидивами/рефрактерным течением АККЛ после ауто/ аллоТГСК составила 76,9 % [70].…”

Section: протокол стадия 3-летняя бсв % источникunclassified

Non-Hodgkin’s Lymphomas in Children: 25-Year Clinical Experience

Валиев

Popa

Levashov

et al. 2016

Клиническая онкогематология

View full text Add to dashboard Cite

НИИ детской онкологии и гематологии ФГБУ «Российский онко-логический научный центр им. Н.Н. Блохина» Минздрава России, Москва, Каширское ш., д. 24, Российская Федерация, 115478 РЕФЕРАТ Актуальность и цели. Современные программы по-лихимиотерапии, в основе которых лежит дифферен-цированный риск-адаптированный подход, позволили рассматривать неходжкинские лимфомы (НХЛ), ранее считавшимися фатальными, как потенциально излечи-мые заболевания. Цель настоящей работы -обобщение и анализ результатов лечения НХЛ за 25-летний период. Conclusion.The obtained results permit to conclude that introduction of achievements of oncoimmunology, molecular biology, and cytogenetics will become the basis for further modification of existing treatment options for NHL.

show abstract

“…Одним из факторов, достоверно улучша-ющих результат ТГСК, является наличие ПР, достигну-той к моменту ТГСК. В работе L. Giulino-Roth 10-лет-няя ОВ больных с рецидивом/рефрактерным течением АККЛ после ауто-/аллоТГСК составила 76,9 % [30].…”

unclassified

Clinical Characteristics and Treatment Results of Pediatric Relapsed/Refractory Non-Hodgkin’s Lymphomas

Валиев¹

2018

Onkogematologiâ

View full text Add to dashboard Cite

Ten-year follow-up of pediatric patients with non-hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation

Abstract: Allogeneic and autologous SCT offer the prospect of durable, disease-free survival for a significant proportion of pediatric patients with relapsed or refractory NHL. Survival is superior among patients with chemotherapy sensitive disease.

Cited by 41 publications

References 33 publications

Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC

Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC

Non-Hodgkin’s Lymphomas in Children: 25-Year Clinical Experience

Clinical Characteristics and Treatment Results of Pediatric Relapsed/Refractory Non-Hodgkin’s Lymphomas

Contact Info

Product

Resources

About